Form 8-K Intellia Therapeutics, For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- Lula, Brazil's iconic working class president, wins historic fourth term in dramatic comeback
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- Accenture shares fall on insider sales and analyst downgrade
- Wall Street closes lower to end rocky week
- Credo Technology shares fall on competition concerns
Intellia Therapeutics (NTLA) PT Raised to $39 at Raymond James
November 5, 2020 12:52 PM ESTRaymond James analyst Steven Seedhouse raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $39.00 (from $27.00) while maintaining a Outperform rating.
... More


